全球脑膜炎双球菌疫苗市场规模（依疫苗类型、最终用户、区域覆盖范围和预测）：

脑膜炎双球菌疫苗市场规模及预测

2024 年脑膜炎双球菌疫苗市场规模价值 48.7 亿美元，预计 2032 年将达到 72 亿美元，2026 年至 2032 年的复合年增长率为 5.54%。

• 脑膜炎双球菌疫苗旨在预防脑膜炎双球菌感染疾病，脑膜炎双球菌感染可导致脑膜炎和败血症等严重。
• 脑膜炎双球菌疫苗预防疾病的有效率至少为 85% 至 100%，有效期至少为 2 年。
• 脑膜炎双球菌疫苗 (MenACWY) 通常为 11-12 岁的青少年接种，16-23 岁的青少年则需要根据个人风险进行加强接种。
• 脑膜炎双球菌疫苗一般被认为可安全用于各种人群，包括孕妇，并持续监测其副作用。

脑膜炎双球菌疫苗的全球市场动态

影响脑膜炎双球菌疫苗市场的关键市场动态是：

关键市场驱动因素

• 脑膜炎球菌疾病发生率上升：全球脑膜炎球菌疾病报告病例数的不断增加是疫苗市场的主要驱动力。例如，2019年，全球约有251万例脑膜炎病例，其中128万例为五岁以下儿童。这一令人担忧的疫情凸显了有效疫苗接种的迫切需求，以预防疫情爆发并保护弱势群体。
• 政府疫苗接种计画：例如，在美国，入学时必须接种疫苗，这导致疫苗接种率很高，尤其是在高风险青少年。
• 公共卫生倡议：世界卫生组织 (WHO) 和疫苗联盟 (Gavi) 等全球卫生组织正在支持低收入国家的疫苗宣传活动，并资助疫苗分发。例如，尼日利亚最近在 Gavi 的资助下推出了新型五价脑膜炎双球菌疫苗 (Men5CV)，以应对日益增长的病菌感染发病率。
• 提高意识和教育宣传活动：提高卫生工作者和公众对脑膜炎球菌病菌感染严重性的认识将推动强调青少年和年轻人接种疫苗重要性的宣传活动需求，这将有助于提高疫苗接种覆盖率。

主要市场挑战：

• 疫苗高成本：脑膜炎双球菌疫苗的成本是疫苗接种的主要障碍，尤其是在中低收入国家。在新兴市场，B群脑膜炎双球菌疫苗等疫苗每剂售价高达150-250美元，远高于每剂通常不到50美元的传统儿科疫苗。如此高昂的价格使得许多人难以获得疫苗，尤其是在医疗预算有限的地区。
• 供应和生产能力有限：脑膜炎双球菌疫苗市场的特点是製造商数量有限，导致供应受限。根据世界卫生组织的数据，全球脑膜炎双球菌疫苗需求量预计约为1.7亿剂，而2019年的供应量估计约为2亿剂。这种差异为满足不同地区，尤其是高发地区的需求带来了挑战。
• 疫苗犹豫和错误讯息：关于疫苗安全性和有效性的错误讯息加剧了这个问题。在识字率低、医疗基础设施匮乏的地区，这种犹豫是疫苗接种的主要障碍。
• 疫苗分发的物流挑战：在偏远和服务不足的地区分发疫苗面临物流挑战，阻碍了疫苗接种。在许多新兴国家，医疗基础设施不足使需要低温运输管理的疫苗储存和分发变得复杂，导致疫苗接种率低。

主要市场趋势：

• 脑膜炎球菌疾病发生率不断上升：根据美国疾病管制与预防中心 (CDC) 预测，全球每年约有 120 万例细菌性脑膜炎病例。发病率的上升凸显了有效疫苗接种策略的迫切需求。
• 世界各国政府正在扩大疫苗接种计划，将脑膜炎双球菌疫苗纳入国家疫苗接种计划。这一趋势针对的是不同人群，包括婴儿、青少年、大学生以及前往流行地区的旅客。例如，随着脑膜炎病例的增加，爱尔兰等国家最近核准了针对青少年的MenACWY疫苗。
• 公众意识提升：医疗保健专业人员和一般大众对脑膜炎球菌病菌感染严重性的认识日益加深。教育宣传活动有助于推广疫苗接种，从而增加了疫苗需求。研究表明，随着家长对脑膜炎球菌病菌感染潜在死亡率的认识不断提高，疫苗接种率可能会上升。
• 疫苗研发技术进步：疫苗技术的创新正在推动市场发展。开发能够预防多种血清群（例如MenABCWY）的多效价疫苗有望提高疫苗接种覆盖率并简化疫苗接种程序，使医护人员和患者都能更轻鬆地接种疫苗。

目录

第一章 引言

• 市场定义
• 市场区隔
• 调查方法

第二章执行摘要

• 主要发现
• 市场概览
• 市集亮点

第三章市场概述

• 市场规模和成长潜力
• 市场趋势
• 市场驱动因素
• 市场限制
• 市场机会
• 波特五力分析

4. 脑膜炎双球菌疫苗市场（依疫苗类型）

• 四价疫苗
• 二价疫苗
• A血清群疫苗

5. 脑膜炎双球菌疫苗市场（依年龄层）

• 新生儿和儿科
• 青少年期和成年早期
• 成人
• 老年人

6. 脑膜炎双球菌疫苗市场（按通路）

• 医院和诊所
• 零售药局
• 网路药局

第七章区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利
• 亚太地区
• 中国
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯聯合大公国

第八章市场动态

• 市场驱动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第九章 竞争态势

• 主要企业
• 市场占有率分析

第十章 公司简介

• GlaxoSmithKline plc（UK）
• Pfizer Inc.（US）
• Sanofi SA（France）
• Baxter International Inc.（US）
• Serum Institute of India Pvt. Ltd.（India）
• Walvax Biotechnology Co., Ltd.（China）

第十一章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第十二章 附录

• 简称列表
• 来源和参考文献

Meningococcal Vaccines Market Size And Forecast

Meningococcal Vaccines Market size was valued at USD 4.87 Billion in 2024 and is projected to reach USD 7.2 Billion by 2032, growing at a CAGR of 5.54% from 2026 to 2032.

• Meningococcal vaccines are designed to protect against infections caused by the bacteria Neisseria meningitidis, which can lead to serious conditions such as meningitis and sepsis.
• Meningococcal vaccines are between 85% and 100% effective in preventing disease for at least two years.
• The MenACWY vaccine is generally given to adolescents at ages 11-12, with a booster at age The MenB vaccine can be given to those aged 16-23 based on individual risk.
• Meningococcal vaccines are generally considered safe for use in various populations, including pregnant individuals, with ongoing monitoring for any adverse effects.

Global Meningococcal Vaccines Market Dynamics

The key market dynamics that are shaping the meningococcal vaccines market include:

Key Market Drivers:

• Increasing Incidence of Meningococcal Disease: The rising number of reported meningococcal disease cases globally is a significant driver for the vaccine market. For instance, in 2019, there were approximately 2.51 million cases of meningitis worldwide, with 1.28 million cases in children under five years old. This alarming prevalence highlights the critical need for effective vaccination to prevent outbreaks and protect vulnerable populations.
• Government Immunization Programs: Many governments have integrated meningococcal vaccines into their national immunization schedules, significantly boosting vaccine In the United States, for example, mandatory vaccination requirements for school and college entry ensure high coverage rates among adolescents, who are particularly at risk.
• Public Health Initiatives: Global health organizations like the World Health Organization (WHO) and Gavi, the Vaccine Alliance, support vaccination campaigns and provide funding for vaccine distribution in low-income countries. For example, Nigeria recently introduced a new 5-in-1 meningococcal vaccine (Men5CV) to combat rising cases, supported by Gavi's financial assistance.
• Awareness and Education Campaigns: Increased awareness among healthcare professionals and the general public about the severity of meningococcal disease drives demand for Campaigns emphasizing the importance of vaccination for adolescents and young adults contributing to higher immunization rates.

Key Market Challenges:

• High Cost of Vaccines: The cost of meningococcal vaccines is a significant barrier to access, particularly in low- and middle-income countries. Prices for vaccines, such as serogroup B meningococcal vaccines, can range from $150 to $250 per dose in developed markets, which is substantially higher than traditional childhood vaccines that typically cost under $50 per dose. This pricing makes it difficult for many populations to afford vaccination, especially where healthcare budgets are limited.
• Limited Supply and Manufacturing Capacity: The meningococcal vaccine market is characterized by a limited number of manufacturers, leading to supply constraints. According to WHO data, the global demand for meningococcal vaccines is projected at around 170 million doses, while the estimated supply was about 200 million doses in 2019. This disparity creates challenges in meeting the needs of various regions, particularly those with high disease prevalence.
• Vaccine Hesitancy and Misinformation: Vaccine hesitancy remains a critical challenge, exacerbated by misinformation regarding vaccine safety and effectiveness. In regions with lower literacy rates and poor healthcare infrastructure, this hesitancy can significantly impede vaccination Public reluctance to vaccinate can lead to lower coverage rates and increased vulnerability to outbreaks.
• Logistical Challenges in Vaccine Distribution: Delivering vaccines to remote or underserved areas poses logistical challenges that can hinder vaccination efforts. In many developing countries, inadequate health infrastructure complicates the storage and distribution of vaccines that require cold chain management, resulting in lower vaccination coverage.

Key Market Trends:

• Growing Incidence of Meningococcal Disease: The increasing prevalence of meningococcal disease is a significant driver of the vaccine According to the CDC, approximately 1.2 million cases of bacterial meningitis are projected to occur globally each year. This rising incidence underscores the urgent need for effective vaccination strategies.
• Expansion of Vaccination Programs: Governments worldwide are expanding their vaccination programs to include meningococcal vaccines in national immunization schedules. This trend targets various demographics, including infants, adolescents, college students, and travelers to endemic For instance, countries like Ireland have recently approved the MenACWY vaccine for teenagers due to rising meningitis cases.
• Increased Public Awareness: There is a growing awareness among healthcare professionals and the general public regarding the seriousness of meningococcal disease. Educational campaigns have been instrumental in promoting vaccination, leading to higher demand for vaccines. Research indicates that as parents become more aware of the potential fatality associated with meningococcal disease, vaccine uptake is likely to increase.
• Technological Advancements in Vaccine Development: Innovations in vaccine technology are driving the market forward. The development of multivalent vaccines that protect against multiple serogroups (e.g., MenABCWY) is expected to enhance coverage and simplify vaccination schedules, making it easier for healthcare providers and patients alike.

Global Meningococcal Vaccine Market Regional Analysis

Here is a more detailed regional analysis of the meningococcal vaccine market:

North America:

• North America is expected to hold an estimated market share of 40.2% in 2024 and has been a leading region with revenues around USD 2.88 Billion in This dominance is attributed to high awareness levels regarding meningococcal diseases and effective vaccination strategies.
• The region benefits from a well-established healthcare system that supports widespread vaccination Strong healthcare infrastructure facilitates easy access to vaccines and ensures efficient distribution, contributing to higher immunization rates.
• Strong government initiatives, such as those from the Centers for Disease Control and Prevention (CDC), promote routine immunization against meningococcal The CDC recommends meningococcal vaccination for adolescents, which significantly boosts vaccine uptake.
• Major pharmaceutical companies in North America, such as GlaxoSmithKline (GSK) and Pfizer, invest heavily in R&D to develop new vaccines and improve existing formulations. This focus on innovation ensures a steady supply of effective vaccines that address emerging strains of Neisseria meningitidis.

Asia Pacific:

• The Asia Pacific region is projected to exhibit the highest compound annual growth rate (CAGR) of 14.7% from 2019 to 2026 in the meningococcal vaccines market, driven by increasing healthcare investments and growing awareness about meningococcal diseases.
• Many governments in the region are expanding their immunization programs to include meningococcal vaccines. For instance, the Indian government has initiated campaigns to vaccinate children against meningitis, recognizing the need to combat rising disease prevalence.
• Rising healthcare spending in developing countries enhances access to vaccines. According to various reports, countries in Asia Pacific are investing more in healthcare infrastructure and vaccine distribution, facilitating broader access to life-saving vaccinations.
• The presence of both domestic and international pharmaceutical companies focusing on vaccine development is increasing competition and innovation in the market. This includes partnerships aimed at improving production and distribution networks within Asia Pacific.

Global Meningococcal Vaccines Market: Segmentation Analysis

The Global Meningococcal Vaccines Market is Segmented on the basis of Product Type, End-User, And Geography.

Meningococcal Vaccines Market, By Product Type

• Quadrivalent Vaccines
• Bivalent Vaccines
• Serogroup A
• Serogroup B
• Serogroup X

Based on Product Type, The market is classified into Quadrivalent Vaccines, Bivalent Vaccines, Serogroup A, Serogroup B, and Serogroup X. Quadrivalent vaccines, which protect against four serogroups of Neisseria meningitidis (A, C, W, and Y), dominate the meningococcal vaccines market with an estimated share of approximately 60% in 2023. This high market share is attributed to their broad coverage and effectiveness in preventing meningococcal disease.

Meningococcal Vaccines Market, By End-User

• Children
• Pre-teens or Teens
• Adults

Based on End-User, the market is classified into Children, Pre-teens or Teens, and Adults. The pre-teens and teens segment accounted for approximately 57.9% of the market share in 2022. This high percentage reflects the increased susceptibility of this age group to meningococcal disease due to their developing immune systems and social interactions.

Meningococcal Vaccines Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, The Global Meningococcal Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to hold an estimated market share of 40.2% in 2024 and has been a leading region with revenues of around USD 2.88 Billion in 2021. This dominance is attributed to high awareness levels regarding meningococcal diseases and effective vaccination strategies.

Key Players

The "Global Meningococcal Vaccines Market" study report will provide valuable insight with an emphasis on the global market including some of the major players such as GlaxoSmithKline plc., Pfizer, Merck & Co., Serum Institute of India, Sanofi, Johnson & Johnson, AstraZeneca, Bavarian Nordic, BIO MED Private Limited, Chongqing Zhifei Biological Products Co., Bio-Manguinhos.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above- mentioned players globally.

• Meningococcal Vaccine Market Recent Developments
• In April 2024, GlaxoSmithKline plc announced the acceptance of their 5-in-1 meningococcal ABCWY vaccine (MenABCWY) for regulatory review by the U.S. FDA, which combines the protective elements of their existing vaccines to target five primary serogroups of Neisseria meningitidis (A, B, C, W, and Y).
• In July 2023, the Serum Institute of India launched MenFive(R), the first conjugate vaccine designed to protect against five predominant causes of meningococcal meningitis, specifically targeting serogroups A, C, W, Y, and X, and aimed at preventing outbreaks in the African meningitis belt.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Meningococcal Vaccine Market, By Type of Vaccine

• Vaccines classified as quadrivalents
• Vaccines classified as bivalents
• Vaccines against Serogroup A

5. Meningococcal Vaccine Market, By Age Range

• Newborns and Children
• Adolescents and Young Adults
• Adults
• Elderly

6. Meningococcal Vaccine Market, By Channel of Distribution

• Hospitals and clinics
• Retail Pharmacies
• Online pharmacies

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• GlaxoSmithKline plc (U.K.)
• Pfizer Inc. (U.S.)
• Sanofi S.A. (France)
• Baxter International Inc. (U.S.)
• Serum Institute of India Pvt. Ltd. (India)
• Walvax Biotechnology Co., Ltd. (China)

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References